Autoimmune Gastrointestinal Dysmotility Global Market Report 2025
상품코드:1760474
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
자가면역 위장 운동 이상증 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안의 성장은 자가면역 질환의 유병률 증가, 진단 기법의 개선, 의료비 지출 증가, 희귀질환 등록 증가, 임상의 교육 개선 등 여러 요인에 기인할 수 있습니다. 이 시기의 주요 동향으로서는 진단 기술의 진보, 면역 요법의 혁신, 신경 소화기 병학의 연구 개발, 운동 조절약의 연구 개발, 맞춤형 치료 어프로치의 채택 등을 들 수 있습니다.
자가면역질환의 유병률 증가는 향후 수 년간 자가면역 위장 운동 이상증 시장의 성장을 가속할 것으로 예측됩니다. 면역 질환 증가는 주로 유전적 소인과 환경 요인의 조합에 기인하고 있으며, 이러한 요인이 결합되어 면역계의 조절이 흐트러져, 신체가 자신의 조직을 공격할 가능성이 높아집니다. 2024년 11월 독일에 본사를 둔 조직 Versorgungsatlas.de가 실시한 설문조사에 따르면 2022년에 조사 대상이 된 7,324만 1,305명 중, 약 630만 4,340명이 적어도 1개의 자가면역질환으로 진단되었고, 유병률은 8.61%가 되었고, 그 결과, 자가면역질환의 유병률의 상승이 자가면역 위장 운동 이상증 시장의 성장에 기여하고 있습니다.
맞춤형 의료가 중시되게 됨으로써 자가면역 위장 운동 이상증 시장의 향후 확대가 기대됩니다. 맞춤형 의료가 주목받게 된 배경에는 유전자 변이의 정확한 식별과 맞춤형 치료의 개발을 가능하게 하는 유전체학의 진보가 있습니다. 이 방법은 치료 효과를 향상시킬 뿐만 아니라 부작용을 최소화하고 복잡한 소화기 질환 관리를 통해 보다 좁은 솔루션을 제공합니다. 신체인 맞춤형 의료연합(PMC)은 미국 식품의약국(FDA)이 2023년에 26건의 개별화 신약을 승인했다고 보고했습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 자가면역 위장 운동 이상증의 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 자가면역 위장 운동 이상증 시장 : 성장률 분석
세계의 자가면역 위장 운동 이상증 시장 실적 : 규모와 성장, 2019-2024년
세계의 자가면역 위장 운동 이상증 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 자가면역 위장 운동 이상증 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 자가면역 위장 운동 이상증 시장 : 치료 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
약
외과적 개입
식사 관리
물리치료
세계의 자가면역 위장 운동 이상증시장 : 약제 클래스별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
소화관 운동 촉진제
항염증제
면역억제제
항생제
세계의 자가면역 위장 운동 이상증시장 : 질환 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
위부전 마비
만성 위성 장폐색(CIPO)
기능성 소화 불량
과민성 장 증후군(IBS)
세리악병
세계의 자가면역 위장 운동 이상증시장 : 유통채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
기타
세계의 자가면역 위장 운동 이상증시장 : 최종사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
병원
클리닉
재택 케어 설정
연구기관
세계의 자가면역 위장 운동 이상증 시장 : 약제 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
면역억제제
코르티코스테로이드
소화관 운동 촉진제
제토제
진경제
항생제
세계의 자가면역 위장 운동 이상증 시장 : 외과적 개입 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
위누조설술
공장 누조설술
결장 누조설술
회장 조설술
유문 성형술
결장절제술
세계의 자가면역 위장 운동 이상증 시장 : 식이 관리 세분화:유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
경장 영양
정맥영양
글루텐 프리 다이어트
엘레멘탈 다이어트
소량의 빈회식
세계의 자가면역 위장 운동 이상증 시장 : 물리치료 서브세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
골반저 요법
복부 마사지 요법
신경근 전기자극(NMES)
바이오 피드백 요법
호흡근 트레이닝
자세 트레이닝
제7장 지역별/국가별 분석
세계의 자가면역 위장 운동 이상증 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 자가면역 위장 운동 이상증 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
자가면역 위장 운동 이상증 시장 : 경쟁 구도
자가면역 위장 운동 이상증 시장 : 기업 프로파일
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Takeda Pharmaceutical Company Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Teva Pharmaceutical Industries Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Chugai Pharmaceutical Co. Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Zeria Pharmaceutical Co. Ltd.
Ironwood Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc.
Dr. Falk Pharma GmbH
Rose Pharma LLC
Parvus Therapeutics Inc.
CinDome Pharma Inc.
Neurogastrx Inc.
Renexxion LLC
ISOThrive Inc.
Ambrose Healthcare Inc.
AnTolRx Inc.
Enteralia Bioscience Srl
Immunic Inc.
Mozart Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
자가면역 위장 운동 이상증 시장 2029년 : 새로운 기회를 제공하는 국가
자가면역 위장 운동 이상증 시장 2029년 : 새로운 기회를 제공하는 부문
자가면역 위장 운동 이상증 시장 2029년 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Autoimmune gastrointestinal dysmotility (AGID) is a rare condition in which the immune system attacks the nerves that control the movement of the digestive tract. This results in slowed or abnormal motility, leading to symptoms such as nausea, bloating, constipation, and intestinal blockage. AGID is often associated with autoimmune diseases or can occur as a paraneoplastic syndrome.
The main treatment options for autoimmune gastrointestinal dysmotility include medications, surgical interventions, dietary management, and physical therapy. Medications aim to manage the disorder by reducing inflammation and improving digestive tract motility. The drug classes used include prokinetic agents, anti-inflammatory drugs, immunosuppressive drugs, and antibiotics. Diseases linked to autoimmune gastrointestinal dysmotility include gastroparesis, chronic intestinal pseudo-obstruction (CIPO), functional dyspepsia, irritable bowel syndrome (IBS), and celiac disease. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution networks. They are used by a variety of end-users, including hospitals, clinics, home care settings, and research institutions.
The autoimmune gastrointestinal dysmotility market research report is one of a series of new reports from The Business Research Company that provides autoimmune gastrointestinal dysmotility market statistics, including the autoimmune gastrointestinal dysmotility industry global market size, regional shares, competitors with the autoimmune gastrointestinal dysmotility market share, detailed autoimmune gastrointestinal dysmotility market segments, market trends, and opportunities, and any further data you may need to thrive in the autoimmune gastrointestinal dysmotility industry. This autoimmune gastrointestinal dysmotility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The autoimmune gastrointestinal dysmotility market size has grown strongly in recent years. It will grow from $1.73 billion in 2024 to $1.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be attributed to several factors, including increasing awareness of rare diseases, the rise in underdeveloped diagnostic practices, a growing number of misdiagnoses with other gastrointestinal disorders, the unavailability of targeted therapies, and delays in research progress.
The autoimmune gastrointestinal dysmotility market size is expected to see strong growth in the next few years. It will grow to $2.30 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to several factors, including the rising prevalence of autoimmune diseases, improvements in diagnostic techniques, increasing healthcare expenditure, the growth of rare disease registries, and better education for clinicians. Key trends during this period include technological advancements in diagnostics, innovations in immunotherapy, developments in neurogastroenterology research, research and development in motility modulators, and the adoption of personalized treatment approaches.
The increasing prevalence of autoimmune disorders is expected to drive the growth of the autoimmune gastrointestinal dysmotility market in the coming years. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells, tissues, or organs, instead of defending them from infections and foreign substances. The rise in autoimmune disorders is mainly attributed to a combination of genetic predisposition and environmental factors, which together disrupt immune system regulation and increase the likelihood of the body attacking its own tissues. Autoimmune gastrointestinal dysmotility plays a key role in identifying and managing underlying autoimmune conditions by revealing immune-mediated damage to the enteric nervous system, linking gastrointestinal symptoms to systemic autoimmune activity. For example, in November 2024, a survey conducted by Versorgungsatlas.de, a Germany-based organization, showed that out of 73,241,305 people surveyed in 2022, around 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61. As a result, the rising prevalence of autoimmune disorders is contributing to the growth of the autoimmune gastrointestinal dysmotility market.
The growing emphasis on personalized medicine is expected to drive the expansion of the autoimmune gastrointestinal dysmotility market moving forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies based on an individual's unique genetic makeup, lifestyle, and environment. The increasing prominence of personalized medicine is largely driven by advancements in genomics, which enable the precise identification of genetic variations and the development of customized treatments. In the case of autoimmune gastrointestinal dysmotility, personalized medicine helps by tailoring therapies to the individual's genetic makeup and specific disease characteristics. This approach not only enhances treatment efficacy but also minimizes side effects, offering more targeted solutions for managing complex gastrointestinal disorders. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from the 12 approved in 2022. Therefore, the increasing focus on personalized medicine is contributing to the growth of the autoimmune gastrointestinal dysmotility market.
Key players in the autoimmune gastrointestinal dysmotility market are focusing on forming strategic partnerships to offer digital therapy solutions for managing autoimmune gastrointestinal dysmotility conditions. Strategic partnerships improve care for autoimmune gastrointestinal dysmotility by providing integrated, virtual-first healthcare with multidisciplinary teams, enhancing symptom management, improving access to care, and increasing cost efficiency. For example, in March 2022, Solera Health, a US-based digital health company, partnered with Oshi Health, a US-based virtual gastrointestinal care company, and Vivante Health, a US-based digital health company. This collaboration aims to deliver advanced digital therapy solutions to support the management and treatment of autoimmune gastrointestinal dysmotility. The partnership focuses on improving patient access to specialized care and enhancing the overall effectiveness of treatments for individuals with gastrointestinal disorders.
Major players in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in autoimmune gastrointestinal dysmotility report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the autoimmune gastrointestinal dysmotility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The autoimmune gastrointestinal dysmotility market consists of revenues earned by entities by providing services such as diagnostic testing, therapeutic treatments, clinical consultations, surgical interventions, rehabilitation and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The autoimmune gastrointestinal dysmotility market also includes sales of diagnostic kits, immunomodulatory drugs, prokinetic agents, and intravenous immunoglobulin (IVIG) therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Autoimmune Gastrointestinal Dysmotility Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on autoimmune gastrointestinal dysmotility market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for autoimmune gastrointestinal dysmotility ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autoimmune gastrointestinal dysmotility market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
3. Autoimmune Gastrointestinal Dysmotility Market Trends And Strategies
4. Autoimmune Gastrointestinal Dysmotility Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Autoimmune Gastrointestinal Dysmotility Growth Analysis And Strategic Analysis Framework
5.1. Global Autoimmune Gastrointestinal Dysmotility PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Autoimmune Gastrointestinal Dysmotility Market Growth Rate Analysis
5.4. Global Autoimmune Gastrointestinal Dysmotility Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Autoimmune Gastrointestinal Dysmotility Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Autoimmune Gastrointestinal Dysmotility Total Addressable Market (TAM)
6.1. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medications
Surgical Interventions
Dietary Management
Physical Therapy
6.2. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prokinetic Agents
Anti-Inflammatory Drugs
Immunosuppressive Drugs
Antibiotics
6.3. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastroparesis
Chronic Intestinal Pseudo-Obstruction (Cipo)
Functional Dyspepsia
Irritable Bowel Syndrome (Ibs)
Celiac Disease
6.4. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Other Distribution Channels
6.5. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Home Care Settings
Research Institutions
6.6. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunosuppressants
Corticosteroids
Prokinetic Agents
Antiemetics
Antispasmodics
Antibiotics
6.7. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastrostomy
Jejunostomy
Colostomy
Ileostomy
Pyloroplasty
Colectomy
6.8. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Dietary Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enteral Nutrition
Parenteral Nutrition
Gluten-Free Diet
Elemental Diet
Small Frequent Meals
6.9. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pelvic Floor Therapy
Abdominal Massage Therapy
Neuromuscular Electrical Stimulation (NMES)
Biofeedback Therapy
Respiratory Muscle Training
Postural Training
7. Autoimmune Gastrointestinal Dysmotility Market Regional And Country Analysis
7.1. Global Autoimmune Gastrointestinal Dysmotility Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Autoimmune Gastrointestinal Dysmotility Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Autoimmune Gastrointestinal Dysmotility Market
9.1. China Autoimmune Gastrointestinal Dysmotility Market Overview
9.2. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Autoimmune Gastrointestinal Dysmotility Market
10.1. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Autoimmune Gastrointestinal Dysmotility Market
11.1. Japan Autoimmune Gastrointestinal Dysmotility Market Overview
11.2. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Autoimmune Gastrointestinal Dysmotility Market
12.1. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Autoimmune Gastrointestinal Dysmotility Market
13.1. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Autoimmune Gastrointestinal Dysmotility Market
14.1. South Korea Autoimmune Gastrointestinal Dysmotility Market Overview
14.2. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Autoimmune Gastrointestinal Dysmotility Market
15.1. Western Europe Autoimmune Gastrointestinal Dysmotility Market Overview
15.2. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Autoimmune Gastrointestinal Dysmotility Market
16.1. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Autoimmune Gastrointestinal Dysmotility Market
18.1. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market
21.1. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market Overview
21.2. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Autoimmune Gastrointestinal Dysmotility Market
22.1. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Autoimmune Gastrointestinal Dysmotility Market
23.1. North America Autoimmune Gastrointestinal Dysmotility Market Overview
23.2. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Autoimmune Gastrointestinal Dysmotility Market
24.1. USA Autoimmune Gastrointestinal Dysmotility Market Overview
24.2. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Autoimmune Gastrointestinal Dysmotility Market
26.1. South America Autoimmune Gastrointestinal Dysmotility Market Overview
26.2. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Autoimmune Gastrointestinal Dysmotility Market
27.1. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Autoimmune Gastrointestinal Dysmotility Market
28.1. Middle East Autoimmune Gastrointestinal Dysmotility Market Overview
28.2. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Autoimmune Gastrointestinal Dysmotility Market
29.1. Africa Autoimmune Gastrointestinal Dysmotility Market Overview
29.2. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Autoimmune Gastrointestinal Dysmotility Market Competitive Landscape And Company Profiles
